Private equity firm Blackstone is nearing a deal to sell Japanese supplement maker Alinamin Pharmaceutical to North Asian buyout fund MBK Partners for 350 billion yen ($2.17 billion), a person with direct knowledge of the matter said on Tuesday.
The deal is expected to be signed soon, said the person, who declined to be identified as the information was private, reports Reuters.
MBK, Blackstone and Alinamin declined to comment.
Blackstone had agreed in August 2020 to acquire Alinamin, then a subsidiary of Takeda Pharmaceutical, according to an announcement from the private equity firm at the time.
Nikkei first reported Blackstone’s planned sale of Alinamin earlier on Tuesday.
MBK aims to use its experience in consumer goods acquisitions to boost Alinamin’s value, the Nikkei reported.
Previously known as Takeda Consumer Healthcare Co, Alinamin provides over-the-counter medicines in Japan.
